Related Articles for PubMed (Select 18271967)

Periodontal disease in a patient receiving Bevacizumab: a case report.

Gujral DM, Bhattacharyya S, Hargreaves P, Middleton GW.

J Med Case Reports. 2008 Feb 13;2:47.

PMID: 18271967 [PubMed - in process]

Related Articles Free article in PMC

Managing patients with metastatic colorectal cancer on bevacizumab.

Lemmens L, Claes V, Uzzell M.

Br J Nurs. 2008 Aug 14-Sep 10;17(15):944-9.

PMID: 18983014 [PubMed - in process]

Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor.

Ignoffo RJ.

Am J Health Syst Pharm. 2004 Nov 1;61(21 Suppl 5):S21-6. Review.

PMID: 15552623 [PubMed - indexed for MEDLINE]

Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.

Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D.

Curr Med Chem. 2006;13(16):1845-57. Review.

PMID: 16842197 [PubMed - indexed for MEDLINE]

Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.

Simpkins F, Belinson JL, Rose PG.

Gynecol Oncol. 2007 Oct;107(1):118-23. Epub 2007 Jul 23.

PMID: 17658587 [PubMed - indexed for MEDLINE]

Bevacizumab in the treatment of colorectal cancer.

Mulcahy MF, Benson AB 3rd.

Expert Opin Biol Ther. 2005 Jul;5(7):997-1005. Review.

PMID: 16018743 [PubMed - indexed for MEDLINE]

Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.

Shih T, Lindley C.

Clin Ther. 2006 Nov;28(11):1779-802. Review.

PMID: 17212999 [PubMed - indexed for MEDLINE]

[Bowel Perforation Associated with Bevacizumab Therapy in Recurrent Ovarian Cancers without Bowel Obstruction or Bowel Involvement.]

Takano M, Kikuchi Y, Kato M, Yoshikawa T, Kita T.

Gan To Kagaku Ryoho. 2008 Nov;35(11):1981-4. Japanese.

PMID: 19011357 [PubMed - in process]

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.

Zhu X, Wu S, Dahut WL, Parikh CR.

Am J Kidney Dis. 2007 Feb;49(2):186-93. Review.

PMID: 17261421 [PubMed - indexed for MEDLINE]

10:

Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab.

Karp JE, Gojo I, Pili R, Gocke CD, Greer J, Guo C, Qian D, Morris L, Tidwell M, Chen H, Zwiebel J.

Clin Cancer Res. 2004 Jun 1;10(11):3577-85.

PMID: 15173063 [PubMed - indexed for MEDLINE]

11:

Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.

Cabebe E, Wakelee H.

Curr Treat Options Oncol. 2007 Feb;8(1):15-27. Review.

PMID: 17634832 [PubMed - indexed for MEDLINE]

12:

Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer.

Hurwitz H.

Clin Colorectal Cancer. 2004 Oct;4 Suppl 2:S62-8. Review.

PMID: 15479481 [PubMed - indexed for MEDLINE]

13:

Sinusoidal obstruction syndrome (veno-occlusive disease) in a patient receiving bevacizumab for metastatic colorectal cancer: a case report.

Agarwal V, Sgouros J, Smithson J, Lodge J, Razack A, Campbell A, Maraveyas A.

J Med Case Reports. 2008 Jul 11;2:227.

PMID: 18620573 [PubMed - in process]

Recent Activity